Analyst Ratings For Paratek Pharmaceuticals (NASDAQ:PRTK)
Today, HC Wainwright raised its price target on Paratek Pharmaceuticals (NASDAQ:PRTK) to $55.00 per share.
Some recent analyst ratings include
- 3/2/2018-Raymond James Financial Reiterated Rating of Strong-Buy .
- 10/24/2017-Robert W. Baird Reiterated Rating of Buy.
- 10/24/2017-Guggenheim initiated coverage with a Buy rating.
- 4/3/2017-Wedbush Reiterated Rating of Outperform .
Recent Insider Trading Activity For Paratek Pharmaceuticals (NASDAQ:PRTK)
Paratek Pharmaceuticals (NASDAQ:PRTK) has insider ownership of 4.90% and institutional ownership of 74.55%.
- On 2/6/2018 Adam Woodrow, VP, sold 14,333 with an average share price of $13.87 per share and the total transaction amounting to $198,798.71.
- On 2/5/2018 Douglas W Pagan, CFO, sold 16,291 with an average share price of $14.22 per share and the total transaction amounting to $231,658.02.
- On 2/5/2018 Evan Loh, COO, sold 3,040 with an average share price of $14.22 per share and the total transaction amounting to $43,228.80.
- On 2/5/2018 Michael Bigham, Chairman, sold 4,000 with an average share price of $14.22 per share and the total transaction amounting to $56,880.00.
- On 2/5/2018 Robert S Radie, Director, sold 3,000 with an average share price of $14.22 per share and the total transaction amounting to $42,660.00.
- On 7/5/2017 Adam Woodrow, VP, sold 3,800 with an average share price of $23.58 per share and the total transaction amounting to $89,604.00.
- On 7/5/2017 Douglas W Pagan, CFO, sold 4,139 with an average share price of $23.58 per share and the total transaction amounting to $97,597.62.
Recent Trading Activity for Paratek Pharmaceuticals (NASDAQ:PRTK)
Shares of Paratek Pharmaceuticals closed the previous trading session at 13.10 up +0.30 2.34% with 300254 shares trading hands.